Loading…

Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis

Direct-acting Antiviral Agents (DAAs) influence serum lipids of patients with Hepatitis C virus (HCV). This paper presents an analysis of the relevant literature to investigate the effects of DAAs in treating hepatitis C to achieve a sustained viral response (SVR) on lipid parameters. PubMed,Web of...

Full description

Saved in:
Bibliographic Details
Published in:Lipids in health and disease 2024-03, Vol.23 (1), p.74-74, Article 74
Main Authors: Mei, Tingting, Huang, Xiaojie, Tang, Shan, Liu, Menglu, Zhang, Wenyan, Yu, Haibin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c515t-8d092eac37eb9630ba1175b8608695fdcdbe1a160495006e2211d9cf1816fa753
container_end_page 74
container_issue 1
container_start_page 74
container_title Lipids in health and disease
container_volume 23
creator Mei, Tingting
Huang, Xiaojie
Tang, Shan
Liu, Menglu
Zhang, Wenyan
Yu, Haibin
description Direct-acting Antiviral Agents (DAAs) influence serum lipids of patients with Hepatitis C virus (HCV). This paper presents an analysis of the relevant literature to investigate the effects of DAAs in treating hepatitis C to achieve a sustained viral response (SVR) on lipid parameters. PubMed,Web of science, Embase and Central databases were searched, with a deadline of September 2023. Studies on the effects of sustained viral response on lipid parameters after DAAs treatment for hepatitis C were selected. The required information was extracted from the included studies, and then the Stata 12.0 was used to analyze the data quantitatively. Of 32 studies, the results showed that total cholesterol (TC) levels increased from the end of treatment (WMD = 20.144, 95%CI = 3.404, 36.884,P = 0.018) to one year after treatment (WMD = 24.900, 95%CI = 13.669, 36.131, P < 0.001). From the end of treatment (WMD = 17.728, 95%CI = 4.375, 31.082, P = 0.009) to one year after treatment (WMD = 18.528, 95%CI = 7.622, 29.433, P < 0.001), the levels of low-density lipoprotein (LDL) were also increased. High-density lipoprotein (HDL) levels were elevated from 4 weeks after treatment (WMD = 6.665, 95%CI = 3.906, 9.424, P < 0.001) to 24 weeks after treatment (WMD = 3.159,95% CI = 0.176, 6.142, P = 0.038). Triglyceride (TG) levels showed no significant change after the treatment. Hepatitis C patients who achieved SVR on DAAs showed the increase of lipid levels and the improvement of hepatic inflammation indicators AST and ALT. This may provide evidence-based medical evidence for the follow-up and monitoring of blood lipids and hyperlipidemia treatment. PROSPERO CRD42020180793.
doi_str_mv 10.1186/s12944-023-01957-2
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b0145164cfe4446092398b8bf81737e5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A785923222</galeid><doaj_id>oai_doaj_org_article_b0145164cfe4446092398b8bf81737e5</doaj_id><sourcerecordid>A785923222</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-8d092eac37eb9630ba1175b8608695fdcdbe1a160495006e2211d9cf1816fa753</originalsourceid><addsrcrecordid>eNptkk9v1DAQxSMEoqXwBTggS1y4pHgc_4m5oGpVaKVKXEDiZjnOePEqsZc4u2i_Pd7dUroI-RBr8t5vPKNXVa-BXgK08n0GpjmvKWtqClqomj2pzoErWQuA708f3c-qFzmvKGVUSfm8OmtaLoFJdl51196jmzNJnuRNnm2I2JNtmOxAJszrFDOSFMkQ1qEnIZIbXNs5zCGTxQdiSd7lGcdScUW-DfiL2NiTEWdb22iHXQ75ZfXM2yHjq_vvRfXt0_XXxU199-Xz7eLqrnYCxFy3PdUMrWsUdlo2tLMASnStpK3Uwveu7xAsSMq1oFQiYwC9dh5akN4q0VxUt0dun-zKrKcw2mlnkg3mUEjT0tipPHRA01HgAiR3HjnnsjRudNu1nW9Blf571scja73pRuwdxrls5AR6-ieGH2aZtgYKi2vdFMK7e8KUfm4wz2YM2eEw2Ihpkw3TgiulGqaK9O0_0lXaTGV7B5VslWZC_FUtbZkgRJ9KY7eHmivVijICY6yoLv-jKqfHMbgU0YdSPzGwo8FNKecJ_cOQQM0-ZuYYM1NiZg4xM3vTm8frebD8yVXzGwwGy3o</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956879255</pqid></control><display><type>article</type><title>Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Mei, Tingting ; Huang, Xiaojie ; Tang, Shan ; Liu, Menglu ; Zhang, Wenyan ; Yu, Haibin</creator><creatorcontrib>Mei, Tingting ; Huang, Xiaojie ; Tang, Shan ; Liu, Menglu ; Zhang, Wenyan ; Yu, Haibin</creatorcontrib><description>Direct-acting Antiviral Agents (DAAs) influence serum lipids of patients with Hepatitis C virus (HCV). This paper presents an analysis of the relevant literature to investigate the effects of DAAs in treating hepatitis C to achieve a sustained viral response (SVR) on lipid parameters. PubMed,Web of science, Embase and Central databases were searched, with a deadline of September 2023. Studies on the effects of sustained viral response on lipid parameters after DAAs treatment for hepatitis C were selected. The required information was extracted from the included studies, and then the Stata 12.0 was used to analyze the data quantitatively. Of 32 studies, the results showed that total cholesterol (TC) levels increased from the end of treatment (WMD = 20.144, 95%CI = 3.404, 36.884,P = 0.018) to one year after treatment (WMD = 24.900, 95%CI = 13.669, 36.131, P &lt; 0.001). From the end of treatment (WMD = 17.728, 95%CI = 4.375, 31.082, P = 0.009) to one year after treatment (WMD = 18.528, 95%CI = 7.622, 29.433, P &lt; 0.001), the levels of low-density lipoprotein (LDL) were also increased. High-density lipoprotein (HDL) levels were elevated from 4 weeks after treatment (WMD = 6.665, 95%CI = 3.906, 9.424, P &lt; 0.001) to 24 weeks after treatment (WMD = 3.159,95% CI = 0.176, 6.142, P = 0.038). Triglyceride (TG) levels showed no significant change after the treatment. Hepatitis C patients who achieved SVR on DAAs showed the increase of lipid levels and the improvement of hepatic inflammation indicators AST and ALT. This may provide evidence-based medical evidence for the follow-up and monitoring of blood lipids and hyperlipidemia treatment. PROSPERO CRD42020180793.</description><identifier>ISSN: 1476-511X</identifier><identifier>EISSN: 1476-511X</identifier><identifier>DOI: 10.1186/s12944-023-01957-2</identifier><identifier>PMID: 38461262</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Antiviral agents ; Antiviral Agents - therapeutic use ; Blood lipids ; Cholesterol ; Direct-acting Antiviral agents ; Drug therapy ; Health aspects ; Hepacivirus - genetics ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatitis C, Chronic - drug therapy ; High density lipoprotein ; Humans ; Hyperlipidemia ; Infections ; Interferon ; Lipid ; Lipids ; Lipoproteins ; Liver cancer ; Liver cirrhosis ; Low density lipoprotein ; Meta-analysis ; Metabolic disorders ; Patients ; Physiological aspects ; Review ; Serum lipids ; Statistical analysis ; Sustained viral response</subject><ispartof>Lipids in health and disease, 2024-03, Vol.23 (1), p.74-74, Article 74</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c515t-8d092eac37eb9630ba1175b8608695fdcdbe1a160495006e2211d9cf1816fa753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924993/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2956879255?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38461262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mei, Tingting</creatorcontrib><creatorcontrib>Huang, Xiaojie</creatorcontrib><creatorcontrib>Tang, Shan</creatorcontrib><creatorcontrib>Liu, Menglu</creatorcontrib><creatorcontrib>Zhang, Wenyan</creatorcontrib><creatorcontrib>Yu, Haibin</creatorcontrib><title>Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis</title><title>Lipids in health and disease</title><addtitle>Lipids Health Dis</addtitle><description>Direct-acting Antiviral Agents (DAAs) influence serum lipids of patients with Hepatitis C virus (HCV). This paper presents an analysis of the relevant literature to investigate the effects of DAAs in treating hepatitis C to achieve a sustained viral response (SVR) on lipid parameters. PubMed,Web of science, Embase and Central databases were searched, with a deadline of September 2023. Studies on the effects of sustained viral response on lipid parameters after DAAs treatment for hepatitis C were selected. The required information was extracted from the included studies, and then the Stata 12.0 was used to analyze the data quantitatively. Of 32 studies, the results showed that total cholesterol (TC) levels increased from the end of treatment (WMD = 20.144, 95%CI = 3.404, 36.884,P = 0.018) to one year after treatment (WMD = 24.900, 95%CI = 13.669, 36.131, P &lt; 0.001). From the end of treatment (WMD = 17.728, 95%CI = 4.375, 31.082, P = 0.009) to one year after treatment (WMD = 18.528, 95%CI = 7.622, 29.433, P &lt; 0.001), the levels of low-density lipoprotein (LDL) were also increased. High-density lipoprotein (HDL) levels were elevated from 4 weeks after treatment (WMD = 6.665, 95%CI = 3.906, 9.424, P &lt; 0.001) to 24 weeks after treatment (WMD = 3.159,95% CI = 0.176, 6.142, P = 0.038). Triglyceride (TG) levels showed no significant change after the treatment. Hepatitis C patients who achieved SVR on DAAs showed the increase of lipid levels and the improvement of hepatic inflammation indicators AST and ALT. This may provide evidence-based medical evidence for the follow-up and monitoring of blood lipids and hyperlipidemia treatment. PROSPERO CRD42020180793.</description><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Blood lipids</subject><subject>Cholesterol</subject><subject>Direct-acting Antiviral agents</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>High density lipoprotein</subject><subject>Humans</subject><subject>Hyperlipidemia</subject><subject>Infections</subject><subject>Interferon</subject><subject>Lipid</subject><subject>Lipids</subject><subject>Lipoproteins</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Low density lipoprotein</subject><subject>Meta-analysis</subject><subject>Metabolic disorders</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Review</subject><subject>Serum lipids</subject><subject>Statistical analysis</subject><subject>Sustained viral response</subject><issn>1476-511X</issn><issn>1476-511X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk9v1DAQxSMEoqXwBTggS1y4pHgc_4m5oGpVaKVKXEDiZjnOePEqsZc4u2i_Pd7dUroI-RBr8t5vPKNXVa-BXgK08n0GpjmvKWtqClqomj2pzoErWQuA708f3c-qFzmvKGVUSfm8OmtaLoFJdl51196jmzNJnuRNnm2I2JNtmOxAJszrFDOSFMkQ1qEnIZIbXNs5zCGTxQdiSd7lGcdScUW-DfiL2NiTEWdb22iHXQ75ZfXM2yHjq_vvRfXt0_XXxU199-Xz7eLqrnYCxFy3PdUMrWsUdlo2tLMASnStpK3Uwveu7xAsSMq1oFQiYwC9dh5akN4q0VxUt0dun-zKrKcw2mlnkg3mUEjT0tipPHRA01HgAiR3HjnnsjRudNu1nW9Blf571scja73pRuwdxrls5AR6-ieGH2aZtgYKi2vdFMK7e8KUfm4wz2YM2eEw2Ihpkw3TgiulGqaK9O0_0lXaTGV7B5VslWZC_FUtbZkgRJ9KY7eHmivVijICY6yoLv-jKqfHMbgU0YdSPzGwo8FNKecJ_cOQQM0-ZuYYM1NiZg4xM3vTm8frebD8yVXzGwwGy3o</recordid><startdate>20240309</startdate><enddate>20240309</enddate><creator>Mei, Tingting</creator><creator>Huang, Xiaojie</creator><creator>Tang, Shan</creator><creator>Liu, Menglu</creator><creator>Zhang, Wenyan</creator><creator>Yu, Haibin</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240309</creationdate><title>Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis</title><author>Mei, Tingting ; Huang, Xiaojie ; Tang, Shan ; Liu, Menglu ; Zhang, Wenyan ; Yu, Haibin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-8d092eac37eb9630ba1175b8608695fdcdbe1a160495006e2211d9cf1816fa753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Blood lipids</topic><topic>Cholesterol</topic><topic>Direct-acting Antiviral agents</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>High density lipoprotein</topic><topic>Humans</topic><topic>Hyperlipidemia</topic><topic>Infections</topic><topic>Interferon</topic><topic>Lipid</topic><topic>Lipids</topic><topic>Lipoproteins</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Low density lipoprotein</topic><topic>Meta-analysis</topic><topic>Metabolic disorders</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Review</topic><topic>Serum lipids</topic><topic>Statistical analysis</topic><topic>Sustained viral response</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mei, Tingting</creatorcontrib><creatorcontrib>Huang, Xiaojie</creatorcontrib><creatorcontrib>Tang, Shan</creatorcontrib><creatorcontrib>Liu, Menglu</creatorcontrib><creatorcontrib>Zhang, Wenyan</creatorcontrib><creatorcontrib>Yu, Haibin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Lipids in health and disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mei, Tingting</au><au>Huang, Xiaojie</au><au>Tang, Shan</au><au>Liu, Menglu</au><au>Zhang, Wenyan</au><au>Yu, Haibin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis</atitle><jtitle>Lipids in health and disease</jtitle><addtitle>Lipids Health Dis</addtitle><date>2024-03-09</date><risdate>2024</risdate><volume>23</volume><issue>1</issue><spage>74</spage><epage>74</epage><pages>74-74</pages><artnum>74</artnum><issn>1476-511X</issn><eissn>1476-511X</eissn><abstract>Direct-acting Antiviral Agents (DAAs) influence serum lipids of patients with Hepatitis C virus (HCV). This paper presents an analysis of the relevant literature to investigate the effects of DAAs in treating hepatitis C to achieve a sustained viral response (SVR) on lipid parameters. PubMed,Web of science, Embase and Central databases were searched, with a deadline of September 2023. Studies on the effects of sustained viral response on lipid parameters after DAAs treatment for hepatitis C were selected. The required information was extracted from the included studies, and then the Stata 12.0 was used to analyze the data quantitatively. Of 32 studies, the results showed that total cholesterol (TC) levels increased from the end of treatment (WMD = 20.144, 95%CI = 3.404, 36.884,P = 0.018) to one year after treatment (WMD = 24.900, 95%CI = 13.669, 36.131, P &lt; 0.001). From the end of treatment (WMD = 17.728, 95%CI = 4.375, 31.082, P = 0.009) to one year after treatment (WMD = 18.528, 95%CI = 7.622, 29.433, P &lt; 0.001), the levels of low-density lipoprotein (LDL) were also increased. High-density lipoprotein (HDL) levels were elevated from 4 weeks after treatment (WMD = 6.665, 95%CI = 3.906, 9.424, P &lt; 0.001) to 24 weeks after treatment (WMD = 3.159,95% CI = 0.176, 6.142, P = 0.038). Triglyceride (TG) levels showed no significant change after the treatment. Hepatitis C patients who achieved SVR on DAAs showed the increase of lipid levels and the improvement of hepatic inflammation indicators AST and ALT. This may provide evidence-based medical evidence for the follow-up and monitoring of blood lipids and hyperlipidemia treatment. PROSPERO CRD42020180793.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>38461262</pmid><doi>10.1186/s12944-023-01957-2</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1476-511X
ispartof Lipids in health and disease, 2024-03, Vol.23 (1), p.74-74, Article 74
issn 1476-511X
1476-511X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b0145164cfe4446092398b8bf81737e5
source Publicly Available Content Database; PubMed Central
subjects Antiviral agents
Antiviral Agents - therapeutic use
Blood lipids
Cholesterol
Direct-acting Antiviral agents
Drug therapy
Health aspects
Hepacivirus - genetics
Hepatitis C
Hepatitis C - drug therapy
Hepatitis C, Chronic - drug therapy
High density lipoprotein
Humans
Hyperlipidemia
Infections
Interferon
Lipid
Lipids
Lipoproteins
Liver cancer
Liver cirrhosis
Low density lipoprotein
Meta-analysis
Metabolic disorders
Patients
Physiological aspects
Review
Serum lipids
Statistical analysis
Sustained viral response
title Effects of sustained viral response on lipid in Hepatitis C: a systematic review and meta-analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A08%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20sustained%20viral%20response%20on%20lipid%20in%20Hepatitis%20C:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Lipids%20in%20health%20and%20disease&rft.au=Mei,%20Tingting&rft.date=2024-03-09&rft.volume=23&rft.issue=1&rft.spage=74&rft.epage=74&rft.pages=74-74&rft.artnum=74&rft.issn=1476-511X&rft.eissn=1476-511X&rft_id=info:doi/10.1186/s12944-023-01957-2&rft_dat=%3Cgale_doaj_%3EA785923222%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c515t-8d092eac37eb9630ba1175b8608695fdcdbe1a160495006e2211d9cf1816fa753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2956879255&rft_id=info:pmid/38461262&rft_galeid=A785923222&rfr_iscdi=true